|
|
Abcellera Biologics Inc (ABCL) |
|
Price: $5.0000
$0.09 
1.833%
|
| Day's High:
| $5
| Week Perf:
| -2.53 %
|
| Day's Low: |
$ 4.88 |
30 Day Perf: |
-10.07 % |
| Volume (M): |
2,438 |
52 Wk High: |
$ 14.97 |
| Volume (M$): |
$ 12,192 |
52 Wk Avg: |
$8.49 |
| Open: |
$4.93 |
52 Wk Low: |
$4.88 |
|
|
| Market Capitalization (Millions $) |
1,445 |
| Shares
Outstanding (Millions) |
289 |
| Employees |
220 |
| Revenues (TTM) (Millions $) |
145 |
| Net Income (TTM) (Millions $) |
-74 |
| Cash Flow (TTM) (Millions $) |
-610 |
| Capital Exp. (TTM) (Millions $) |
69 |
Abcellera Biologics Inc
Abcellera Biologics Inc is a biotech company specializing in the development of fully human monoclonal antibodies. The company was founded in 2012 by a team of scientists from the University of British Columbia, and it has since grown to become one of the world's leading developers of innovative antibody-based therapies.
Using its proprietary technology, Abcellera is able to rapidly discover and develop human antibodies against a wide range of diseases, including infectious diseases, cancer, and autoimmune disorders. The company's technology is based on a high-throughput screening platform that can analyze millions of immune cells in a matter of days, allowing for the rapid identification of promising candidates.
Abcellera's technology is particularly well-suited to the development of therapies against rapidly evolving viruses, such as COVID-19. In early 2020, Abcellera partnered with pharmaceutical company Eli Lilly to develop a monoclonal antibody treatment for COVID-19. The resulting drug, bamlanivimab, was granted emergency use authorization by the US Food and Drug Administration in November 2020.
In addition to its work on COVID-19, Abcellera is also developing therapies for a range of other diseases, including cancer and autoimmune disorders. The company has partnerships with a number of pharmaceutical companies, including Pfizer, GSK, and Novartis, and it has raised over $500 million in funding to date.
Abcellera's innovative approach to developing antibody-based therapies has earned the company numerous accolades, including being named one of the most innovative companies in biotech by Fast Company. With its cutting-edge technology and strong partnerships with the pharmaceutical industry, Abcellera is well-positioned to continue making breakthroughs in the development of novel therapeutics.
Company Address: 2215 Yukon Street Vancouver 0 BC
Company Phone Number: 559-9005 Stock Exchange / Ticker: NASDAQ ABCL
| ABCL is expected to report next financial results on November 07, 2023. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Cannapharmarx Inc
The first quarter of 2023 has shown significant promise for Cannapharmarx Inc, a major player in the pharmaceutical preparations industry. While the company has not revealed any top-line figures yet, industry observers are examining the operating shortfall of $-0.720277 million, shedding light on the positive performance of the firm during this period. By comparing it to previous quarters and assessing other growth indicators, we can anticipate a bullish outlook for Cannapharmarx Inc in the near future.
Reduced Losses and Growing Revenue:
In the first quarter of 2022, Cannapharmarx Inc experienced an operating shortfall of $-0.715558 million. However, with effective cost-cutting measures and revenue growth strategies, the company has managed to improve its financial performance in Q1 2023. The company's losses of $-2.072 million in the first quarter of 2022 have been reduced to $-1.413 million, showcasing a significant improvement in their bottom line. This reduction of losses is indicative of a more efficient and profitable operation.
|
|
Benitec Biopharma Inc
Financial News Report: Benitec Biopharma Inc Reports Loss in Fiscal Year 2023
Benitec Biopharma Inc, a major pharmaceutical preparations company, recently released its financial results for the fiscal interval ending June 30, 2023. The company reported a net loss of $-4.661 million, compared to a deficit of $-5.067 million in the corresponding reporting season a year ago.
In terms of earnings per share (EPS), Benitec Biopharma Inc experienced a decline from $-0.16 per share in the previous reporting season to $-0.17 per share in the current period. However, this is an improvement compared to the earnings of $-0.62 per share a year before the reporting season.
|
|
Kintara Therapeutics Inc
Bearish Outlook for Kintara Therapeutics Inc as Fourth Quarter Earnings Paint a Bleak Picture
The fourth quarter earnings report for Kintara Therapeutics Inc (KTRA) has sent shockwaves through the market as the pharmaceutical preparations sector advisors begin to analyze the data. With an operating profit of $3.349 million, KTRA has failed to disclose its revenue for the April to June 2023 financial reporting period. However, comparisons with the previous year's performance highlight a worrying trend.
In the fourth quarter of 2022, KTRA recorded a significantly higher operating profit of $5.458 million, indicating a sharp decline in operating earnings by -38.64%. This decline is a cause for concern as it reflects a substantial decrease in the company's efficiency and overall financial performance. Furthermore, the management has failed to address the issue of diminishing returns, leading to a net deficit of $-14.66 million and a troubling revenue of $0.00 million in the fiscal period 2023.
|
|
Integrated Biopharma Inc
Integrated Biopharma Inc recently released its financial results for the fiscal period ending June 30, 2023. The report highlights a decrease in revenue, net earnings, as well as a decline in operating and net margins. Additionally, the company's stockpiles remain below the previous year's level. This article aims to outline the key facts from the financial results and provide an analysis of Integrated Biopharma Inc's performance.
Financial Results Overview:
1. Earnings per Share (EPS): In the fiscal period ending June 30, 2023, Integrated Biopharma Inc recorded an EPS of $0.00 per share, compared to $0.05 per share in the same period a year ago. This figure also remained consistent with the preceding reporting period.
|
|
Rezolute Inc
Despite some positive momentum in recent weeks, Rezolute Inc (RZLT) remains an overlooked player in the Major Pharmaceutical Preparations sector. The company's financial numbers paint a gloomy picture, indicating significant operating shortfalls and a net deficit.
In the fourth quarter of 2023, Rezolute Inc reported an operating shortfall of $-14.238 million, demonstrating a worsening financial situation. Although the company has not disclosed its revenue, it is clear that its current revenue figures are not helping to alleviate concerns. Comparing it to the fourth quarter of 2022, where Rezolute Inc reported an operating shortfall of $-11.3 million, it is evident that the company's financial woes have only worsened over time.
The shortfall of $-12.728 million reported in the comparable three months preceding last year is also a cause for concern. The fact that this figure increased from $-9.423 million is alarming and suggests a lack of progress in addressing financial challenges. Additionally, the company reported a net deficit of $-51.79 million, further highlighting its troubled financial state.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.25 $ |
| Revenues (TTM) |
0.5 $
|
| Cash Flow (TTM) |
- |
| Cash |
2.75 $
|
| Book Value |
4.14 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.25 $
|
| Revenues (TTM) |
0.5 $ |
| Cash Flow (TTM) |
- |
| Cash |
2.75 $
|
| Book Value |
4.14 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
0.72%